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DNA encoding ricin B chain was fused to that encoding the E. coli OmpA signal peptide using the expression secretion 
vector PIN-1 1 I-ompA. When induced, E. coli cells transformed with the recombinant plasmid express ricin B chain. The 
recombinant product accumulates in the periplasmic space in a soluble, biologically active form. 
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1. INTRODUCTION 
Ricin, the cytotoxic lectin from Ricinus com- 
munis seeds, is a heterodimer consisting of a toxic 
polypeptide (the A chain) joined to a cell-binding, 
galactose-specific lectin (the B chain) by a single 
disulphide bond (review [l]). The A chain 
catalytically inactivates eukaryotic ribosomes by 
specifically depurinating 28 S ribosomal RNA 
[2,3]. Penetration of the A chain into the 
cytoplasm of target cells begins when the holotoxin 
binds to cell surface galactose residues and is 
achieved when the B chain facilitates the transloca- 
tion of A chain across the membrane of an in- 
tracellular compartment during subsequent endo- 
cytosis [4,5]. The two B chain functions (cell bind- 
ing and A chain translocation) are believed to 
reside on separate domains of the polypeptide [6], 
although this remains to be convincingly estab- 
lished [7]. 
Whole ricin or its purified A chain have been 
widely used for the construction of immunotoxins 
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(review [8,9]). Immunotoxins are hybrid molecules 
in which cytotoxins or their toxic subunits are 
chemically coupled to cell-reactive monoclonal an- 
tibodies. At present the in vivo application of 
whole ricin immunotoxins is not feasible since the 
ricin B chain galactose-binding capacity overrides 
the cell-type targeting specificity conferred by the 
antibody [9]. 
One approach to this problem is to genetically 
modify. ricin B chain using protein engineering 
techniques. The ricin precursor gene has been 
cloned [ 10,l l] and B chain residues responsible for 
galactose binding have been identified [12]. Such 
residues could be modified by oligonucleotide site- 
specific mutagenesis and expression of DNA en- 
coding modified ricin B chain. It is hoped that this 
approach might produce mutant B chain no longer 
able to bind galactose but still capable of poten- 
tiating A chain translocation. A prerequisite for 
this work is the ability to express biologically 
active, recombinant ricin B chain. Previous work 
has shown that this can be achieved in eukaryotic 
hosts if the recombinant B chain is directed into 
the endomembrane system using homologous or 
heterologous eukaryotic signal sequences [ 13- 151. 
In the present paper we show that biologically ac- 
tive ricin B chain can also be produced in E. coli 
by using a bacterial signal sequence which targets 
the product to the periplasmic space. 
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2. MATERIALS AND METHODS 2.5. Identification of recombinant B chain 
2.1. Materials 
Escherichia coli strains TG2 (A(lacpro) thi, staA, hsdR_, 
hsdM_, recA-, sclC 3OO::TnlO F’, traD36, proAB, laclg, IacZ 
DM15), DHl (F- recA1, evdA1, gyrA96, thi-I, hsdRI7(rkmk+, 
Supt44, relAZ)) and JA221 (Ipp-, hsdM+, trpt5, leuB6, lacy, 
recA1, F’lacP, lac+, pro’) were used as indicated. Restriction 
endonucleases, Tq ligase and biotinylated protein A/streptavi- 
din-horseradish peroxidase were obtained from Amersham 
(Bucks, England) and isopropyl P-D-thio-galactopyranoside 
(IPTG), ampicillin and asialofetuin were obtained from Sigma 
(Poole, England). Vector PIN-111-ompA3 [16] and E. coli 
strain JA221 were kindly provided by Dr M. Inouye. 
Samples, including crude lysates and periplasmic fractions, 
were analysed by SDS-polyacrylamide gel electrophoresis [19] 
and Western blotting [20]. Blots were probed with polyclonal 
antibodies raised in rabbits against ricin B chain purified from 
Ricinus communis seeds [21], and were developed using the 
biotinylated protein A/streptavidin-peroxidase system (ac- 
cording to the suppliers’ instructions). Ricin B chain was en- 
zymically deglycosylated using endo-N-acetylglucosaminidase 
H 1221. 
2.6. Lectin activity of recombinant ricin B chain 
2.2. General methods 
Plasmid DNAs were prepared by the alkaline lysis method 
[17] and purified by centrifugation in cesium chloride-ethidium 
bromide. Restriction enzyme digests and ligations were carried 
out as recommended by the suppliers. 
2.3. Construction of PIN-I1 I-ompA3 ricin (R)B 
To avoid possible expression of a truncated ricin B chain 
caused by translation initiation at Met76, utilising the upstream 
sequence GGAG as a Shine-Dalgarno sequence (unpublished), 
Met76 was converted to an Be codon by oligonucleotide site- 
directed mutagenesis using standard procedures [18] (Grierson, 
C., unpublished). This was accomplished in Ml3 using a ricin 
B chain encoding BamHI fragment as a template and the DNA 
was recloned into pUC19 to generate pTCA0.3. The 5’-end of 
this ricin B chain encoding sequence was then excised with 
BamHI and KpnI and the 328 bp fragment ligated with the 
900 bp KpnI-Sal1 fragment of pUC8pRB (a plasmid containing 
ricin B chain preceded by the preproricin signal sequence) and 
with the large BamHI-Sal1 fragment of expression vector 
PIN-Ill-ompA3 in a tripartite ligation. This strategy is sum- 
marised in fig. 1. 
Recombinant ricin B chain present in various fractions was 
assayed for lectin activity by its ability to bind to immobilised 
asialofetuin, a glycoprotein with terminal galactose residues. 
The assay was a modification [14] of a procedure described 
previously [23]. Briefly, asialofetuin was used to coat the wells 
of a microtitre plate, samples containing recombinant B chain 
were added and, after washing, biologically active ricin B chain 
bound to the asialofetuin was measured by adding rabbit anti- 
ricin B chain antibodies followed by ‘251-labelled protein A. By 
comparison to a calibration curve produced using native ricin 
B chain, this radioimmunoassay was used to quantify recombi- 
nant ricin B chain production. 
3. RESULTS AND DISCUSSION 
2.4. Expression of ricin B chain in E. coli 
Recombinant plasmid PIN-I 1 I-ompA3RB was introduced in- 
to E. co/i by calcium chloride-mediated transformation. 
Bacteria were grown at various temperatures ( ee section 3) in 
the presence of ampicillin (50pg/ml) and IPTG (1 mM) in 
either (a) nutrient broth supplemented with glucose (0.4%), 
MgS04 (10 mM) and MgClz (10 mM), or (b) defined medium 
containing casamino acids (lvo), glucose (0.4%), MgS04 
(10 mM), MgClz (10 mM), tryptophan (40 mM), CaC12 
(IOOpM), vitamin Bl (1 mM), Na2HP04 (4 mM), KHzP04 
(2 mM), NaCl (8 mM) and NHXI (20 mM). Cultures were 
grown to an Asso of 0.6-0.8 and the cells were harvested by cen- 
trifugation. To prepare the periplasmic fraction, the cells (1 1 
culture) were resuspended in 20 ml of 10 mM Tris-HCI, pH 7.5, 
containing 20% (w/v) sucrose and kept on ice for 10 min. After 
repelleting the cells by centrifugation at 4”C, they were 
resuspended in 10 ml of 10 mM Tris-HCI, pH 7.5, sup- 
plemented where appropriate with 1 mM lactose, and kept on 
ice for a further IO min. After centrifugation at 18000 rpm for 
20 min, the supernatant was taken as the periplasmic fraction. 
Where appropriate, this fraction was further centrifuged at 
100000 x g in a Beckman airfuge. 
Previous studies have shown that biologically 
active recombinant ricin B chain can be expressed 
in eukaryotic cells when the recombinant product 
is directed into the endomembrane system of the 
host cell using an appropriate N-terminal signal se- 
quence [ 13-151. Cytoplasmically expressed recom- 
binant ricin B chain aggregates, presumably 
because of incorrect folding and aberrant 
disulphide bond formation, and is devoid of 
biological activity (unpublished). In E. coli, the ex- 
pression of eukaryotic proteins stabilised by in- 
tramolecular disulphide bonds may lead to the 
intracellular accumulation of inactive polypeptide 
aggregates [24]. When the expressed product is 
directed into the E. coli periplasmic space, 
however, the recombinant protein often folds into 
the biologically active, native conformation and 
forms the correct disulphide bonds. 
Inouye and his colleagues [16] have developed a 
high expression secretion vector, PIN-1 1 1-ompA, 
which targets recombinant products to the 
periplasmic space of E. cob. This vector contains 
the signal sequence of a major E. coli outer mem- 
brane protein, the OmpA protein, to which the 
heterologous protein is fused. Secretion into the 
periplasmic space is accompanied by OmpA signal 
peptide cleavage and disulphide bond formation, 
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resulting in a correctly folded, biologically active 
recombinant protein [25-291. 
We have followed this strategy to produce 
recombinant ricin B chain in E. coli. E. coli TG2 
cells were transformed with vector alone or with a 
recombinant plasmid containing the ricin B chain 
DNA insert (PIN-11 I-ompA3RB, fig.1) and were 
grown at either 30 or 37°C. Total proteins present 
in various cell fractions after cell lysis were 
separated by SDS-PAGE and blotted onto 
nitrocellulose paper. A typical blot probed with 
anti-ricin B chain antibodies is shown in fig.2. 
Lysates from cells grown at 30°C (fig.2, lane 1) or 
37°C (fig.2, lane 2) contained material which 
Barn-Kpn / 
\ Km-Sal 
r I 
I Fusion at 5'end I 
mcs B chain 
..CAG GCC GGA ATT CCA AGC TTG GAT CCT.. 
,.Gln Ala Gly Ile Pro Ser Leu Asp Pro.. 
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I sig;al 
I 
cleavage site 
B chain 
residue 6 
I I 
Fig. 1. Construction of the ricin B chain expression plasmid. A 
328 bp BumHI-KpnI fragment and a 900 bp KpnI-SalI 
fragment, which together contained the entire ricin B chain 
coding sequence, were ligated into BumHI-WI cut 
plN-11 l-ompA3 to produce PIN-1 1 I-ompA3RB. Upon 
expression of this construct he 5 N-terminal residues of native 
ricin B chain (Ala-Asp-Val-Cys-Met-) will be replaced with 5 
residues from the multiple cloning site (MCS) (Gly-Ile-Pro-Ser- 
Leu-). Restriction sites indicated are B, BumHI; K, KpnI; S, 
Fig.2. Expression of ricin B chain in E. coii TG2 cells. 
Transformants were grown at 30 or 37°C and, after lysis, 
proteins present in various fractions were separated by SDS- 
PAGE, blotted onto nitrocellulose and probed with anti-ricin B 
chain antibodies. Lanes: 1 and 2, total lysates from 30 and 37°C 
grown cells, respectively; 3, total lysate from cells transformed 
with vector lacking the ricin B chain DNA insert; 4 and 5, 
periplasmic fractions from 30 and 37°C grown cells; 6 and 7, 
cell pellet from 30 and 37°C grown cells; 8, deglycosylated ricin 
B chain (the upper band has had one oligosaccharide chain 
removed, the lower band has had both chains removed); 9, 
San; P, PstI; X, XhoI. native ricin B chain. 
reacted strongly with the antibodies, and which 
had an apparent molecular mass equivalent o that 
of deglycosylated ricin B chain (fig.2, lane 8). This 
product was not detected in lysates from cells 
transformed with vector alone (fig.2, lane 3). Ricin 
B chain was detected in the periplasmic fraction 
prepared from cells grown at 30°C (fig.2, lane 4) 
and 37°C (fig.2, lane 5) and in the cell/debris pellet 
obtained after rupturing the outer membrane to 
release the periplasmic components (fig.2, lanes 6 
and 7). 
The bulk of the periplasmic ricin B chain pro- 
duced by E. coli strain TG2 was soluble, although 
some aggregation had apparently occurred. Fig.3 
shows that when the periplasmic fraction (fig.3, 
lane 2) was centrifuged at 100000 x g in a 
Beckman airfuge, ricin B chain was detected in 
both the supernatant (fig.3, lane 3) and in the 
pellet (fig.3, lane 4). (It should be noted that in the 
preparation of fig.3 the whole of the pellet was run 
in lane 4 but only l/10 volume of the corre- 
sponding supernatant was run in lane 3 .) Fig. 3 also 
clearly indicates that the recombinant B chain 
product ran as a doublet. We assume that the 
smaller molecular mass band represents mature B 
chain from which the ompA signal peptide had 
been removed, while the less mobile band 
represents unprocessed product. The extent to 
385 
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Fig.3. High-speed centrifugation of the periplasmic fraction 
from E. coli TG2 cells expressing ricin B chain. Proteins were 
separated by SDS-PAGE, blotted and probed with anti-ricin B 
chain antibodies. Lanes: 1, total lysate from cells transformed 
with vector lacking insert; 2, periplasmic fraction; 3, a 100 pl 
aliquot taken from the supernatant after high-speed 
centrifugation of 1 ml of periplasmic fraction; 4, the total pellet 
after high-speed centrifugation of 1 ml of periplasmic fraction; 
5, ricin B chain. 
Fig.4. Expression of ricin B chain in different E. colt strains. E. 
cob strains JA221 (lane l), TG2 (lane 2) and DHI (lane 3) were 
transformed with plN-11 I-ompA3RB. Total lysates were 
probed for ricin B chain as for figs 2 and 3. Lane 4, 
deglycosylated ricin B chain. 
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Table 1 
Effect of culturing conditions on the yield of biologically active 
ricin B chain expressed in E. co/i strain JA221 
Media Lactose IPTG Growth B chain Control 
(1 mM) induction temp. (“C) (ug/l) &g/l) 
NB 
NB 
NB 
NB 
NB 
Defined 
Defined 
Defined 
Defined 
Defined 
+ 
+ 
30 1 0.1 
21 1.5 0 
25 12.5 0.3 
20 15 0.6 
20 20 0 
20 100 0.5 
18 24 0 
18 800 0.7 
18 400 0 
18 1000 0.7 
which the ompA signal sequence was processed 
was host strain dependent. Thus, while the recom- 
binant product was expressed as a doublet in TG2 
cells (fig.4, lane 2) or DHI cells (fig.4, lane 3), only 
a single processed species was produced by JA221 
cells (fig.4, lane 1). 
All three host strains produced biologically ac- 
tive B chain as determined by its ability to bind to 
immobilised asialofetuin. The amount of active B 
chain produced was markedly influenced by 
culturing conditions. Table 1 shows the effect of 
media, growth temperature, the presence of lactose 
in media and IPTG induction on recombinant B 
chain production by E. co/i strain JA221. The op- 
timal yield of recombinant product was observed 
for cells growing on defined medium supplemented 
with lactose at low temperature (18’C) after IPTG 
induction. For strain JA221, these conditions 
resulted in the production of 1 mg active ricin B 
chain per litre of culture. The actual level of ex- 
pression was significantly higher than this but the 
radioimmunoassay used here only quantifies 
biologically active product. Upon storage this solu- 
ble, active product tended to aggregate with a con- 
comitant decline in its ability to bind galactose. 
Notwithstanding this, the present report clearly 
shows that soluble, active recombinant ricin B 
chain can be produced in E. coli when the product 
is directed to the periplasmic space. 
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